BIOGEN INC (BIIB)
US09062X1037 - Common Stock
Interesting BIIB Put And Call Options For July 2025
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Unusual volume S&P500 stocks in Thursday's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Thursday. Stay informed about the market activity below.
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:...
Biogen Enters Oversold Territory (BIIB)
Noteworthy Friday Option Activity: DPZ, BIIB, AXL
December 27th Options Now Available For Biogen (BIIB)
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart.
Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment...
Notable Wednesday Option Activity: BIIB, HUM, CLX
Biogen (BIIB) Q3 2024 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2024.
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
The biotech giant also raised full-year EPS guidance.
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment.
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.Collaboration leverages...
See How Biogen Ranks Among Analysts' Top Picks With Strong Buyback Activity
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Robin Kramer, Chief Accounting Officer, to Succeed Him
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Robin Kramer, Chief Accounting Officer, to Succeed Him...
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last...
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical...
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Fewer contenders means fewer constraints on expanding market share.
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral presentation to...